SUMMARY In a follow up study of 11 patients with mixed connective tissue disease the levels of antibodies to nuclear ribonucleoprotein (nRNP) as measured by an enzyme linked immunosorbent assay (ELISA) were related to clinical activity of disease. To assess the relation between anti-nRNP levels and disease activity the levels of total immunoglobulin G, IgM rheumatoid factor (IgM RF), and antibodies to an unrelated antigen (tetanus toxoid) were determined simultaneously. No significant changes in anti-nRNP levels were noted in four patients with minor activity of disease. Major flares of disease were observed in seven patients. Clinical symptoms were preceded by a rise in anti-nRNP level in these patients unless they received immunosuppressive agents before the exacerbation. Conversely, when a rise in anti-nRNP level occurred a major flare of disease was followed in all but one case. Anti-nRNP levels fell during clinical improvement whether or not immunosuppressive treatment was given. All patients showed parallel fluctuations in anti-nRNP, IgM RF, and total immunoglobulin G levels. Furthermore, parallel fluctuations were seen in the levels of anti-nRNP and antibodies to tetanus toxoid except in one patient. We 
Fluctuations in anti-nRNP levels in patients with MCTD 801 In a previous report we described an enzyme linked immunosorbent assay (ELISA) for measurement of anti-nRNP. " ' We showed that the ELISA is as sensitive as counterimmunoelectrophoresis in the detection of anti-nRNP.
In the present study we have evaluated the measurement of anti-nRNP by ELISA as a guide for disease activity in patients with mixed connective tissue disease. To delineate the specific relation between fluctuations in anti-nRNP levels and disease activity we determined simultaneously levels of antibodies to an unrelated antigen (tetanus toxoid), and levels of IgM rheumatoid factor, another autoantibody frequently present in the sera of these patients. Since autoantibodies in connective tissue disease belong predominantly to the immunoglobulin G (IgG) class" we also measured total IgG in all serum samples. The results of our study show that major flares of disease are accompanied by fluctuations in anti-nRNP. These fluctuations are, however, not specific for anti-nRNP.
Patients and methods

PATIENTS AND SERA
Serum samples containing antibodies to nRNP-as determined by counterimmunoelectrophoresis (CIE)-were taken from 11 patients. Clinical data of the patients are presented in Table 1 . The mean period of follow up of the patients was 35 months (range 17-51 months). Seven patients were treated with immunosuppressive therapy (corticosteroids, azathioprine, cyclophosphamide, or methotrexate (MTX)) at some time during the study period. Patients were seen at regular intervals at the outpatient department during periods of relatively stable disease activity and were admitted to the hospital during flares of major disease activity. Serum samples were drawn at each visit to the outpatient department and every two weeks during admission. All sera were also tested for antibodies to Four patients (Nos 1-4) did not suffer from major flares of disease during the entire period of the follow up study (Table 1 ). In these patients there was no significant change in the levels of anti-nRNP or the index of disease activity as assessed by Kendall's analysis. An example of antibody profiles in patient No 2 with stable disease activity is given in Fig. 1 .
Fourteen major flares of disease occurred in seven patients (Nos 5-11. Table 1 ) during the follow up period. In two cases (Nos 8 and 10) a flare of disease was already present at the beginning of the follow up. Thus changes in anti-nRNP levels preceding the disease manifestations could be studied in relation to 12 flares (Table 3 ). In three cases (Nos 5, 7 ( Fig.   2 ) and 11 (Fig. 4) ) no immunosuppressive therapy was given in the period before the first exacerbation. A rise of anti-nRNP preceded the major disease manifestations in these patients. Nine episodes of major disease activity developed in three patients (Nos 6 (Fig. 3) . 8. and 9) on immunosuppressive therapy. Four episodes. all serositis, were not preceded by a rise in anti-nRNP levels. In five episodes anti-nRNP levels rose before the exacerbation. These data are summarised in Table 3 .
Six out of the seven patients with major disease manifestations were treated with immunosuppressive agents (Table 1 . Figs 2-4) during the follow up period. In all these patients a decrease in anti-nRNP levels was observed associated with clinical recovery. In one patient (No 5) clinical improvement and concomittant decrease of anti-nRNP levels occurred before institution of immunosuppressive agents.
We related fluctuations in anti-nRNP levels to changes in disease activity as determined by a scoring system based on the diversity and the severity of the clinical symptoms. In five out of the seven patients with major flares of disease a significant correlation was found between antinRNP levels and index of disease activity during the follow up period (Table 4) .
PREDICTIVE VALUE OF A RISE OF ANTI-nRNP LEVELS
A rise of the anti-nRNP level was seen 10 times in the group of 11 patients. In nine out of these 10 cases this rise was followed by a major flare of disease. In most cases anti-nRNP levels rose in- 
SPECIFICITY OF THE FLUCTUATIONS IN ANTI-nRNP LEVELS
Rank order correlations were calculated to determine whether fluctuations in the levels of anti-nRNP were related to fluctuations in the levels of antibodies of other specificities. Another autoantibody (IgM RF), an antibody to an unrelated antigen (tetanus toxoid), and total IgG levels were studied. In two out of the four patients with stable disease activity a significant correlation was found between fluctuations in anti-nRNP and antitetanus antibodies. Anti-nRNP levels correlated with the levels of total IgG in one of them. In six out of seven patients with major manifestations of disease a significant correlation was found between the fluctuations in anti-nRNP levels and the fluctuations in the levels of IgM RF, antibodies to tetanus toxoid, and total IgG ( Table 4) . The remaining patient, No 7, showed a parallel rise of anti-nRNP and total IgG levels without any change in the level of antitetanus antibody, whereas IgM RF was persistently negative (Fig. 2) . Results are summarised in tests and levels of complement component C3, as these immunological parameters are probably related to the levels of anti-nRNP antibody. When the manifestations of disease most commonly encountered are included and arbitrary points assigned to each manifestation the index combines both of the above approaches. It does not discriminate, however, between one single manifestation of major activity and several manifestations of minor activity. For this reason disease activity was not only approached by the defined index of disease activity but also by the occurrence of major manifestations (myositis, serositis, and vasculitis in our group of patients). 
